Control of Risk Factors for Cardiovascular Disease among Multinational Patient Population in the Arabian Gulf

Ibrahim Al-Zakwani1,2, Wael Al-Mahmeed3, Mohamed Arafah4, Ali T. Al-Hinai5, Abdullah Shehab6, Omer Al-Tamimi7, Mahmoud Al-Awadhi8, Shorook Al-Herz9, Faisal Al-Anazi10, Khalid Al-Nemer11, Othman Metwally12, Akram Al-Khadra13, Mohammed Fakhry13, Hossam Elghetany14, Abdel R. Medani15, Afzal H. Yusufali15, Obaid Al-Jassim15, Omar Al-Hallaq16, Fahad O.A.S. Baslaib17, Haitham Amin18, Raul D. Santos19, Khalid Al-Waili20, Khamis Al-Hashmi21 and Khalid Al-Rasadi20,*

1Department of Pharmacology & Clinical Pharmacy, College of Medicine & Health Sciences, Sultan Qaboos University, Muscat, Oman; 2Gulf Health Research, Muscat, Oman; 3Heart and Vascular Institute - Cleveland Clinic, Abu Dhabi, UAE; 4King Saud University, Riyadh, KSA; 5Ministry of Health, Muscat, Oman; 6UAE University, Al Ain, UAE; 7Hamad Medical Corporation, Doha, Qatar; 8Al Amiri Hospital, Kuwait City, Kuwait; 9King Fahad National Guard Hospital, Riyadh, KSA; 10Ministry of Health, Riyadh, KSA; 11Al-Imam Mohammad Ibn Saud Islamic University (IMSIU), School of Medicine, Riyadh, KSA; 12King Fahad General Hospital, Jeddah, KSA; 13King Fahad Hospital of the University, Khobar, KSA; 14Soliman Fakieh Hospital, Jeddah, KSA; 15Dubai Hospital, Dubai Health Authority, Dubai, UAE; 16American Hospital, Dubai, UAE; 17Rashid Hospital, Dubai Health Authority, Dubai, UAE; 18Bahrain Defense Force Hospital, Manama, Bahrain; 19Lipid Clinic Heart Institute, University of Sao Paulo, Sao Paulo, Brazil; 20Department of Biochemistry, Sultan Qaboos University Hospital, Muscat, Oman; 21Department of Physiology, College of Medicine & Health Sciences, Sultan Qaboos University, Muscat, Oman

Abstract: We evaluated the control of cardiovascular disease (CVD) risk factors among patients with atherosclerotic cardiovascular disease (ASCVD) in the Centralized Pan-Middle East Survey on the undertreatment of hypercholesterolaemia (CEPHEUS) in the Arabian Gulf. Of the 4398 enrolled patients, overall mean age was 57 ± 11 years, 60% were males, 13% were smokers, 76% had diabetes, 71% had metabolic syndrome and 78% had very high ASCVD risk status. The proportion of body mass index <25 kg/m², HbA1c ≤7% (in diabetics), low-density lipoprotein cholesterol (LDL-C) <2.6 mmol/L (100 mg/dL) and <1.8 mmol/L (70 mg/dL) for high and very high ASCVD risk cohorts, respectively and controlled blood pressure (<140/90 mmHg) was 14, 26, 31% and 60%, respectively. Only 1.4% of the participants had all of their CVD risk factors controlled with significant differences among the countries (P < .001). CVD risk goal attainment rates were significantly lower in those with very high ASCVD risk compared with those with high ASCVD risk status (P < .001). Females were also, generally, less likely to attain goals when compared with males (P < .001).

Keywords: Cardiovascular diseases, obesity, blood pressure, diabetes mellitus, non-HDL cholesterol, LDL cholesterol, Arabian Gulf.

INTRODUCTION

The increase in the cardiovascular disease (CVD)-associated mortality rate in the Middle East is one of the highest in the World [1]. In addition, studies such as the Gulf Registry of Acute Coronary Events (Gulf RACE) and the international case-control analysis of the risk factors for a first myocardial infarction (MI) conducted in >15000 patients in 52 countries (INTERHEART) reported that patients in the Middle East present with heart attacks, 10-12 years earlier than those in Western countries [2, 3].

Some multi-national studies have focused on single CVD risk factor goal attainment [4-6] but others did address several CVD risk factors [7-12] There is a high prevalence of obesity, diabetes mellitus (DM), metabolic syndrome (MetS), dyslipidaemia and hypertension in the Arabian Gulf [13-20], but data on the control of these factors among the multi-national patient population at high and very high atherosclerotic cardiovascular disease (ASCVD) risk in the region is limited [11, 12].

The objective of this study was to evaluate the control of CVD risk factors among the multi-national patient population with high and very high ASCVD risk status in the Centralized Pan-Middle East Survey on the undertreatment of hypercholesterolaemia (CEPHEUS) in the Arabian Gulf.
METHODS

The methods have been described [21]. Briefly, the CEPHEUS study was a multi-centre non-interventional survey of patients on lipid lowering drugs (LLDs) in 6 Middle Eastern countries (Saudi Arabia, United Arab Emirates, Oman, Qatar, Bahrain and Kuwait). A total of 5457 patients were enrolled in this survey from outpatient clinics by 177 specialists and primary care physicians. The study was conducted between November 22, 2009 and July 7, 2010. The inclusion criteria were: patients ≥18 years of age taking LLDs for ≥3 months, with no dose change for a minimum of 6 weeks.

A fasting blood sample was obtained for measurement of total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), apolipoprotein A1 (Apo A1), apolipoprotein B (Apo B), glucose and glycated haemoglobin A1c (HbA1c). Blood samples were collected in 3 tubes (5 ml in a gel tube, 2 ml in a fluoride tube and 2 ml in an ethylenediaminetetra-acetic acid (EDTA) tube). The blood samples were shipped by air courier and the tests were performed at the King Faisal Specialist Hospital and Research Centre (Riyadh, Saudi Arabia). All the laboratory tests underwent internal and external quality control checks. Criteria for ASCVD risk status was derived from the National Lipid Association (NLA) recommendations for patient-centered management of dyslipidaemia Part 1 – Executive Summary [22].

High risk group included patients with ≥3 major ASCVD risk factors, DM (type 1 or 2) with 0-1 other major ASCVD risk factor or LDL-C ≥190 mg/dL (5.0 mmol/L) (severe hypercholesterolaemia). The very high risk group included ASCVD and DM with ≥2 other major ASCVD risk factors [22].

With regards to body mass index (BMI), classifications were based on international (World Health Organization) reference ranges, Normal weight was <25 kg/m², overweight was 25-30 kg/m² and obese was >30 kg/m². As per the recent reference ranges. Normal weight was <25 kg/m², overweight were based on international (World Health Organization) With regards to body mass index (BMI), classifications were based on international (World Health Organization) reference ranges, Normal weight was <25 kg/m², overweight was 25-30 kg/m² and obese was >30 kg/m². As per the recent reference ranges. Normal weight was <25 kg/m², overweight were based on international (World Health Organization) reference ranges. Normal weight was <25 kg/m², overweight were based on international (World Health Organization) reference ranges. Normal weight was <25 kg/m², overweight were based on international (World Health Organization) reference ranges. Normal weight was <25 kg/m², overweight were based on international (World Health Organization) reference ranges. Normal weight was <25 kg/m², overweight were based on international (World Health Organization) reference ranges. Normal weight was <25 kg/m², overweight were based on international (World Health Organization) reference ranges.

RESULTS

A total of 5457 patients participated in the survey. Laboratory data were missing for 160 patients, 6 patients were underage and 15 patients missed the ASCVD risk level data. Non-smoking statin combination and other dyslipidaemic therapy were (94% n = 4136) were on statin monotherapy. Patients on LDL-C targets for the high ASCVD risk patients were <100 mg/dL (2.6 mmol/L) and <70 mg/dL (1.8 mmol/L) for those with high and very high ASCVD risk status, respectively [22]. Blood pressure (BP) goals were adapted from the Eighth National Joint Committee (JNC-8) 2014 Hypertension Guideline Management Algorithm. BP goals for those without DM and ≥60 years and those <60 years were <150/90 and <140/90 mmHg, respectively. For those with DM irrespective of age, the BP goal was <140/90 mmHg [24].

Statistical Analysis

For continuous variables, mean and standard deviation were used to summarize the data. For categorical variables, frequencies and percentages were reported. Differences between groups were analysed using Pearson’s χ² tests (or Fisher’s exact tests for cells <5). For continuous variables, analyses were performed using univariate ordinary least squares (OLS) regression. An a priori two-tailed level of significance was set at 0.05. Statistical analyses were conducted using STATA version 13.1 (STATA Corporation, College Station, TX, USA).

Ethics Approval

This study complied with the Declaration of Helsinki. The study had approval from the internal review bodies/ethics committees of each participating institution. Informed written consent was also obtained from all patients enrolled in the study.
Table 1. Demographic and clinical characteristics of the CEPHEUS cohort stratified by country.

| Characteristic                        | All (n = 4398) | Bahrain (n = 66) | KSA (n = 3259) | Kuwait (n = 46) | Oman (n = 399) | Qatar (n = 97) | UAE (n = 531) | P       |
|---------------------------------------|----------------|-----------------|----------------|----------------|----------------|----------------|--------------|---------|
| Gulf citizen                         | 3312 (75%)     | 52 (79%)        | 2614 (80%)     | 38 (83%)       | 398 (99%)      | 8 (8.3%)       | 202 (38%)    | <.001   |
| Male, n (%)                           | 2621 (60%)     | 52 (80%)        | 1854 (57%)     | 12 (26%)       | 207 (52%)      | 92 (95%)       | 404 (76%)    | <.001   |
| Age, mean ± SD, years                 | 57±11          | 56±7            | 56±11          | 57±12          | 58±12          | 56±12          | 58±11        | <.001   |
| Weight, mean ± SD, kg                | 82±17          | 84±19           | 83±17          | 86±22          | 76±18          | 80±15          | 81±16        | <.001   |
| Waist, mean ± SD, cm                 | 104±14         | 102±13          | 105±14         | 105±16         | 102±13         | 101±11         | 101±12       | <.001   |
| BMI, mean ± SD, kg/m²                | 31±7           | 30±6            | 32±7           | 34±9           | 31±7           | 28±5           | 30±6         | <.001   |
| BMI ≥30 kg/m², n (%)                 | 2323 (53%)     | 27 (41%)        | 1835 (56%)     | 29 (63%)       | 203 (52%)      | 28 (29%)       | 201 (38%)    | <.001   |
| Smoking, n (%)                        | 561 (13%)      | 13 (20%)        | 455 (14%)      | 3 (6.5%)       | 34 (7%)        | 11 (11%)       | 62 (12%)     | <.001   |
| Hypertension, n (%)                  | 3075 (70%)     | 58 (88%)        | 2195 (67%)     | 34 (74%)       | 307 (77%)      | 56 (58%)       | 425 (80%)    | <.001   |
| Coronary heart disease               | 1616 (37%)     | 43 (65%)        | 898 (28%)      | 7 (15%)        | 177 (44%)      | 87 (90%)       | 404 (76%)    | <.001   |
| Peripheral artery disease            | 149 (3.4%)     | 0               | 117 (3.6%)     | 0              | 15 (3.8%)      | 6 (6.2%)       | 11 (2.1%)    | .092    |
| Cardiovascular disease               | 192 (4.4%)     | 4 (6.1%)        | 132 (4.1%)     | 3 (6.5%)       | 30 (7.5%)      | 2 (2.1%)       | 21 (4.0%)    | .030    |
| Diabetes mellitus                    | 3350 (76%)     | 40 (61%)        | 257 (8.4%)     | 1 (2.3%)       | 23 (6.0%)      | 45 (46%)       | 305 (57%)    | <.001   |
| Metabolic syndrome                   | 2948 (71%)     | 43 (74%)        | 2287 (73%)     | 32 (70%)       | 252 (65%)      | 51 (56%)       | 283 (63%)    | <.001   |

ASCVD risk status

| statin monotherapy                   | 4136 (94%)     | 62 (94%)        | 3064 (94%)     | 43 (93%)       | 383 (96%)      | 89 (92%)       | 495 (93%)    | .510    |
| Atorvastatin                         | 1786 (43%)     | 6 (9.7%)        | 1389 (45%)     | 40 (93%)       | 0              | 66 (74%)       | 285 (58%)    | <.001   |
| Rosuvastatin                         | 486 (12%)      | 45 (73%)        | 257 (8.4%)     | 1 (2.3%)       | 23 (6.0%)      | 7 (7.9%)       | 153 (31%)    | <.001   |
| Simvastatin                          | 1792 (43%)     | 8 (13%)         | 1378 (45%)     | 2 (4.7%)       | 359 (94%)      | 5 (5.6%)       | 40 (8.1%)    | <.001   |
| Statin combination                   | 220 (5.0%)     | 4 (6.1%)        | 171 (5.3%)     | 1 (2.2%)       | 8 (2.0%)       | 5 (5.2%)       | 31 (5.8%)    | .095    |
| Others                               | 42 (1.0%)      | 0              | 24 (0.7%)      | 2 (4.4%)       | 8 (2.0%)       | 3 (3.1%)       | 5 (0.9%)     | .006    |

Lipids on treatment, mean ± SD, mmol/L, unless specified otherwise

| Lipid group                           | All (n = 4398) | Bahrain (n = 66) | KSA (n = 3259) | Kuwait (n = 46) | Oman (n = 399) | Qatar (n = 97) | UAE (n = 531) | P       |
|---------------------------------------|----------------|-----------------|----------------|----------------|----------------|----------------|--------------|---------|
| LDL-C                                 | 2.53±0.94      | 1.90±0.63       | 2.59±0.93      | 2.35±0.68      | 2.68±1.03      | 2.13±0.81      | 2.20±0.84    | <.001   |
| HDL-C                                 | 1.15±0.31      | 1.10±0.26       | 1.17±0.31      | 1.18±0.33      | 1.14±0.31      | 0.99±0.25      | 1.08±0.30    | <.001   |
| Apo B, g/L                            | 0.91±0.27      | 0.76±0.21       | 0.93±0.27      | 0.87±0.18      | 0.95±0.29      | 0.85±0.26      | 0.83±0.25    | <.001   |
| Non-HDL-C                             | 3.15±1.09      | 2.47±0.67       | 3.21±1.09      | 3.08±0.84      | 3.30±1.18      | 2.85±0.94      | 2.80±0.98    | <.001   |
| TG                                    | 1.74±1.26      | 1.52±0.70       | 1.80±1.30      | 1.65±1.01      | 1.54±1.40      | 1.73±1.18      | 1.55±0.93    | <.001   |

Blood pressure, mean ± SD, mmHg, unless specified otherwise

| blood pressure                         | All (n = 4398) | Bahrain (n = 66) | KSA (n = 3259) | Kuwait (n = 46) | Oman (n = 399) | Qatar (n = 97) | UAE (n = 531) | P       |
|---------------------------------------|----------------|-----------------|----------------|----------------|----------------|----------------|--------------|---------|
| Systolic blood pressure               | 133±18         | 139±18          | 132±18         | 125±16         | 140±22         | 130±18         | 132±18       | <.001   |
| Diastolic blood pressure              | 79±10          | 77±10           | 79±10          | 78±10          | 77±11          | 75±9           | 78±11        | <.001   |

Abbreviations: SD, standard deviation; BMI, body mass index; ASCVD, atherosclerotic cardiovascular disease; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Apo B, apolipoprotein B; TG, triglycerides.

Criteria for ASCVD risk status was adapted from the National Lipid Association criteria for atherosclerotic cardiovascular disease. High risk group included patients with ≥3 major ASCVD risk factors, diabetes mellitus (type 1 or 2) with 0/1 major ASCVD risk factor and LDL-C ≥190 mg/dL (5.0 mmol/L) (severe hypercholesterolaemia). Very high ASCVD risk group included those with coronary heart disease, peripheral artery disease, cerebrovascular disease and diabetes mellitus with ≥2 other major ASCVD risk factors.

Age (n=8), gender (n=14), weight (n=4), BMI (n=15), metabolic syndrome (n=227), Apo B (n=14), TG (n=1) and blood pressure (n=8) were missing in some subjects.
Table 2. Cardiovascular risk factors goal achievements stratified by country and ASCVD risk status.

| Characteristic                  | Overall (N = 4398) | Bahrain (n = 66) | KSA (n = 3259) | Kuwait (n = 46) | Oman (n = 399) | Qatar (n = 97) | UAE (n = 531) | P      |
|--------------------------------|--------------------|------------------|---------------|----------------|---------------|---------------|---------------|--------|
| No smoking, n (%)              | 3837 (87%)         | 53 (80%)         | 2804 (86%)    | 43 (93%)       | 382 (96%)     | 86 (89%)      | 469 (88%)     | <.001  |
| In high ASCVD                   | 848 (88%)          | 5 (56%)          | 714 (88%)     | 9 (100%)       | 77 (93%)      | 3 (60%)       | 40 (78%)      | .001   |
| In very high ASCVD              | 2989 (87%)         | 48 (84%)         | 2090 (85%)    | 34 (92%)       | 305 (97%)     | 83 (90%)      | 429 (89%)     | <.001  |
| BMI <25 kg/m²                   | 598 (14%)          | 13 (20%)         | 365 (11%)     | 5 (11%)        | 72 (18%)      | 28 (29%)      | 115 (22%)     | <.001  |
| In high ASCVD                   | 98 (10%)           | 1 (11%)          | 76 (9.4%)     | 1 (11%)        | 13 (16%)      | 1 (20%)       | 6 (12%)       | .318   |
| In very high ASCVD              | 500 (15%)          | 12 (21%)         | 289 (12%)     | 4 (11%)        | 59 (19%)      | 27 (30%)      | 109 (23%)     | <.001  |
| HbA1c, <7%, in diabetics only   | 868 (26%)          | 13 (32%)         | 651 (24%)     | 23 (55%)       | 75 (31%)      | 9 (20%)       | 97 (32%)      | <.001  |
| In high ASCVD                   | 156 (27%)          | n/a              | 141 (27%)     | 5 (56%)        | 7 (22%)       | 0             | 3 (21%)       | .343   |
| In very high ASCVD              | 712 (26%)          | 13 (32%)         | 510 (24%)     | 18 (55%)       | 68 (32%)      | 9 (20%)       | 94 (32%)      | <.001  |
| LDL-C goal attainment           | 1348 (31%)         | 41 (62%)         | 926 (28%)     | 14 (30%)       | 103 (26%)     | 41 (42%)      | 223 (42%)     | <.001  |
| In high ASCVD                   | 445 (46%)          | 7 (78%)          | 369 (46%)     | 4 (44%)        | 37 (45%)      | 2 (40%)       | 26 (51%)      | .501   |
| In very high ASCVD              | 903 (26%)          | 34 (60%)         | 557 (23%)     | 10 (27%)       | 66 (21%)      | 39 (42%)      | 197 (41%)     | <.001  |
| BP goal attainment              | 2622 (60%)         | 31 (48%)         | 1933 (59%)    | 29 (63%)       | 217 (55%)     | 70 (74%)      | 342 (64%)     | .001   |
| In high ASCVD                   | 723 (71%)          | 5 (56%)          | 624 (77%)     | 6 (67%)        | 51 (62%)      | 1 (20%)       | 36 (71%)      | .002   |
| In very high ASCVD              | 1899 (55%)         | 26 (47%)         | 1309 (53%)    | 23 (62%)       | 166 (53%)     | 69 (77%)      | 306 (64%)     | <.001  |

Abbreviations: ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; LDL-C, low-density lipoprotein cholesterol; BP, blood pressure. Criteria for ASCVD risk status was adapted from the National Lipid Association criteria for atherosclerotic cardiovascular disease. High risk group included patients with ≥3 major ASCVD risk factors, diabetes mellitus (type 1 or 2) with ≥1 major ASCVD risk factor and LDL-C ≥190 mg/dL (5.02 mmol/L) (severe hypercholesterolemia). Very high risk group included ASCVD (coronary heart disease, peripheral artery disease, cerebrovascular disease) and diabetes mellitus with ≥2 other major ASCVD risk factors. Therapeutic lipoprotein targets for the high ASCVD risk patients were LDL-C <2.6 mmol/L (100 mg/dL) and LDL-C <1.8 mmol/L (70 mg/dL) for the very high ASCVD risk patients. BP goals were adapted from the new JNC-8 2014 Hypertension Guideline Management Algorithm. BP goals for those without diabetes mellitus (DM) and <60 years were <150/90 mmHg and <140/90 mmHg, respectively. For those with DM irrespective of age, the BP goal was <140/90 mmHg. BMI (n=15), HbA1c (n=13) and blood pressure (n=8) were missing in some subjects.

Goal attainment rates of the different CVD risk factors (smoking, BMI, HbA1c, LDL-C and BP) stratified by high and very high ASCVD risk patients is outlined in Fig. (1). The number of patients that achieved 1, 2, 3 and 4 goals were (20%; n = 877), (37%; n = 1629), (29%; n = 1283) and (11%; n = 471), respectively. Only 1.4% (n = 61) of the subjects had all the 5 CVD risk factors at goal. Patients with very high ASCVD risk were more likely to make goal if they had only 1 risk factor (23 vs. 8.4%; P < .001). However, for those with more CVD risk factors, those with very high ASCVD risk were less likely to attain goal when compared with those with only high ASCVD risk (3 risk factors (27% vs. 38%; P < .001) and 4 risk factors (8.7 vs. 18%; P < .001)).

Fig. (2) summarizes goal attainment rates (smoking, BMI, HbA1c, LDL-C, and BP) in very high ASCVD risk patients stratified by gender. Males were more likely to attain BMI <25 kg/m² (18 vs. 9%; P < .001), LDL-C (30 vs. 20%; P < .001) and BP (58 vs. 53%; P < .001) goal achievements when compared with females. Females on the other hand were less likely to smoke (98 vs. 81%; P < .001).

Fig. (3) summarizes goal attainment rates (smoking, BMI, HbA1c, LDL-C, and BP) in high ASCVD risk patients stratified by gender. Females were less likely to smoke (98 vs. 76%; P < .001). However, males were more likely to attain their BMI target of <25 kg/m² (14 vs. 7%; P = .001).

DISCUSSION

Data on the control of CVD risk factors among the multinational patient population with high and very high ASCVD risk groups in the Arabian Gulf is scarce [11, 12]. The current study evaluated the CVD risk factors and the goal attainments in a multi-national patient population on LLDs with high and very high ASCVD in the CEPHEUS study in the Arabian Gulf. The prevalence of obesity (>30 kg/m²), DM, MetS, hypertension and smoking were 53, 76, 41, 70 and 13%, respectively.

Similar findings were observed in the two multi-national studies with patients from the Arabian Gulf [11, 12]. The Africa Middle East Cardiovascular Epidemiological (ACE) study, which surveyed 4378 outpatients (2337 outpatients from 8 countries in Africa, and 2041 outpatients from 6 countries in the Middle East including Saudi Arabia, United Arab Emirates and Kuwait) with intermediate and high risk CVD status, the prevalence of obesity (>30 kg/m²), DM, MetS, hypertension and smoking were 37, 25, 43 and 25%, respectively [11]. The Reduction of Atherothrombosis for Continued Health
Fig. (1). Overall goal attainment rates of the different cardiovascular risk factors (smoking, BMI, HbA1c, LDL-C, and BP) stratified by atherosclerotic cardiovascular disease (ASCVD) risk status in the Arabian Gulf (N = 4398).

**Abbreviations:** BMI, body mass index; LDL-C, low-density lipoprotein cholesterol; BP, blood pressure.

Criteria for ASCVD risk status was adapted from the National Lipid Association criteria\(^2\) for atherosclerotic cardiovascular disease. High risk group included patients with \(\geq 3\) major ASCVD risk factors, diabetes mellitus (type 1 or 2) with \(0–1\) major ASCVD risk factor and LDL-C \(\geq 190\) mg/dL (5.02 mmol/L) (severe hypercholesterolemia). Very high ASCVD risk group included coronary heart disease, peripheral artery disease, cerebrovascular disease and diabetes mellitus with \(\geq 2\) other major ASCVD risk factors.

CVD risk factor goal attainments were no smoking, BMI <25 kg/m\(^2\), HbA1c <7% and LDL-C for the high and very high ASCVD risk patients was LDL-C < 100 mg/dL (2.6 mmol/L) and LDL-C <70 mg/dL (1.8 mmol/L), respectively.

BP goals were adapted from the new JNC-8 2014 Hypertension Guideline Management Algorithm.\(^2\) BP goals for those without diabetes mellitus (DM) and \(\geq 60\) years and those <60 years were <150/90 mmHg and <140/90 mmHg, respectively. For those with DM irrespective of age, the BP goal was <140/90 mmHg.

Fig. (2). Overall goal attainment rates (smoking, BMI, HbA1c, LDL-C, and BP) in very high atherosclerotic cardiovascular disease (ASCVD) risk patients stratified by gender in the Arabian Gulf (N = 3431).

**Abbreviations:** BMI, body mass index; LDL-C, low-density lipoprotein cholesterol; BP, blood pressure.

Criteria for ASCVD risk status was adapted from the National Lipid Association criteria\(^2\) for atherosclerotic cardiovascular disease. High risk group included patients with \(\geq 3\) major ASCVD risk factors, diabetes mellitus (type 1 or 2) with \(0–1\) major ASCVD risk factor and LDL-C \(\geq 190\) mg/dL (5.02 mmol/L) (severe hypercholesterolemia). Very high ASCVD risk group included coronary heart disease, peripheral artery disease, cerebrovascular disease and diabetes mellitus with \(\geq 2\) other major ASCVD risk factors.

CVD risk factor goal attainments were no smoking, BMI <25 kg/m\(^2\), HbA1c <7% and LDL-C for the very ASCVD risk patients was LDL-C < 70 mg/dL (1.8 mmol/L).

BP goals were adapted from the new JNC-8 2014 Hypertension Guideline Management Algorithm.\(^2\) BP goals for those without diabetes mellitus (DM) and \(\geq 60\) years and those <60 years were <150/90 mmHg and <140/90 mmHg, respectively. For those with DM irrespective of age, the BP goal was <140/90 mmHg.
(REACH) study was conducted in 68000 patients from 44 countries including 4 Middle Eastern countries from Israel (374 patients), Lebanon (120 patients), Saudi Arabia (196 patients) and the United Arab Emirates (150 patients) in stable outpatients with established CVD or at least 3 risk factors for atherothrombosis [7]. Based on 840 patients from the Middle East, the prevalence of obesity, DM, hypertension and smoking were 38.6, 52.3, 80.2 and 46%, respectively [12]. Although the prevalence of dyslipidaemia in the two previous studies were 70 and 34.1%, respectively, in the current study all the patients were sampled from outpatients with dyslipidaemia and on LDLs.

The most striking findings of this study are the high prevalence of obesity, DM, MetS and hypertension, which are in agreement with other studies carried out in the region [13-19]. In the Gulf RACE project, a multi-national registry of 8176 patients admitted with acute coronary syndromes (ACS) in 6 Arabian Gulf countries, 67% were overweight or obese, 40% of the patients had a history of DM and 46% had MetS [2, 13, 15]. Patients with DM and MetS were more likely to have congestive heart failure [19, 25]. Another finding from the present study is the relatively younger population with very high ASCVD risk, which is consistent with findings from the Gulf RACE and REACH registries in the Middle East [2, 12]. In the Gulf RACE, patients with ACS were a decade or two younger than what had been observed in international registries and younger patients with ACS have a higher relative increase in mortality related to heart failure [2].

The CVD risk factors goal attainments for the overall cohort in the current study were BMI <25 kg/m² (14%), HbA1c <7% (26%), LDL-C (31%) and BP <140/90 mmHg (60%). Smoking, HbA1c, LDL-C and BP goals were significantly less likely to be attained in the very high ASCVD risk patients when compared with those with high ASCVD risk. The Cepheus study (current study) was associated with better LDL-C target (46 vs. 21%) and BP goal (60 vs. 53%) attainments compared with the regional Gulf RACE study [13]. In the REACH registry in the Middle East, many patients in the overall group had a total cholesterol of >5.29 mmol/L (30.2%), a BP of >140/90 mmHg (43.5%) or a serum glucose of >7 mmol/L (37.6%) [12]. In the same study, patients with only CVD risk factors were more likely to have an uncontrolled risk factor than patients with established CVD.

In the current study, women with very high ASCVD risk status were less likely to be smokers and attain their BMI, LDL-C and BP goals than men. In the high ASCVD risk group, women were significantly less likely to attain their BMI goal than men. This may be attributed to several factors like high prevalence of obesity, DM, dyslipidaemia and hypertension in women compared with men in the region [26-29]. In the Gulf RACE and Gulf RACE-2, obesity, hypertension, DM and dyslipidaemia were more prevalent in women than in men and were generally treated less conservatively compared with men [26, 27]. Both the prevalence of these factors and management differences contributed to worse outcomes in women (e.g. in-hospital mortality and heart failure) [26, 27].

Overall, 80% in our study had at least one uncontrolled risk factor and this percentage was even higher in the high ASCVD risk group (90%). This finding is in agreement with the REACH registry in the Middle East [12] where 75.6% in

![Fig. (3). Overall goal attainment rates (smoking, BMI, HbA1c, LDL-C, and BP) in the high atherosclerotic cardiovascular disease (ASCVD) risk patients stratified by gender in the Arabian Gulf (N = 967).](image-url)
the overall group had at least one uncontrolled risk factor. This finding highlights the significant gap in controlling CVD risk factors among Arabian Gulf population and therefore further work is needed to overcome the barriers to risk factor control in the triad of patient, physician and healthcare system. Goal attainment of the CVD risk factors may not be achieved because of physician lack of familiarity with treatment goals, inappropriate follow-up, and patient non-adherence with, or intolerance of, medications and the lesser use of evidence-based medications especially in women. There is a high priority need for more education, awareness campaigns for healthcare providers and the public and for screening programs for early identification of risk factors and implementation of healthy lifestyle strategies.

The present analysis has several limitations. The data was collected from patients on LLDs and practice patterns in selected centers that participated in this multi-national study, may not accurately reflect the national trends within the respective countries. In addition, apart from the LLDs, no data were available for the treatment of other CVD risk factors. Furthermore, the findings are limited by the cross-sectional design and reliance on one-time measurements of risk factors, as well as the lack of data on other variables such as social class and diet that may affect CVD risk. In addition, we did not use any verification method for smoking status in this study. Nevertheless, the agreement of the study findings with other studies in the region help validate our results. Further epidemiological studies are needed to estimate the prevalence of CVD risk factors in the region, to observe any changes in prevalence rate over time and to assess the effect of prevention using longitudinal data collection methods that would provide accurate statistics on CVD risk factors prevalence, including details in key population subgroups like women and children [28, 29].

CONCLUSION

A large proportion of patients in the Arabian Gulf are uncontrolled in terms of CVD risk factors, especially in women and in those with very high ASCVD risk status. The findings highlight the significant gaps in controlling CVD risk factors among the Arabian Gulf population. More work is needed to overcome the barriers to risk factor control in the triad of patient, physician and healthcare system.

CONFLICT OF INTEREST

The authors disclose that they have no significant relationships with or financial interests in any commercial companies related to this study or article.

ACKNOWLEDGEMENTS

We thank the patients, physicians, nurses, and support staff who participated in the CEPHEUS project for their invaluable cooperation. We would also like to thank ClinArt MENA for organizing the survey.

The CEPHEUS project was sponsored by AstraZeneca. The sponsor had no involvement in the study conception or design; analysis; or interpretation of data; writing; review, or approval of the manuscript; or the decision to submit the manuscript for publication.

REFERENCES

[1] Ramahi TM. Cardiovascular disease in the Asia Middle East region: global trends and local implications. Asia Pac J Public Health 2010; 22(3 Suppl): S35-S95.
[2] Zubaid M, Rashied WA, Almahmeed W, et al. Management and outcomes of Middle Eastern patients admitted with acute coronary syndromes in the Gulf Registry of Acute Coronary Events (Gulf RACE). Acta Cardiol 2009; 64(4): 439-46.
[3] Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364(9438): 937-52.
[4] Waters DD, Brotons C, Chiang CW, et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low density lipoprotein cholesterol goals. Circulation 2009; 120(1): 28-34.
[5] Wang YR, Alexander GC, Stafford RS. Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med 2007; 167(2): 141-7.
[6] Al Sifri SN, Almahmeed W, Azar S, et al. Results of the Dyslipidemia International Study (DYSIS)-Middle East: clinical perspective on the prevalence and characteristics of lipid abnormalities in the setting of chronic statin treatment. PLoS One 2014; 9(1): e84350.
[7] Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295(2): 180-9.
[8] Kotseva K, Wood D, De Backer G, et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009; 16(2): 121-37.
[9] Kotseva K, Wood D, De Backer G, et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in 12 European countries. Lancet 2009; 373(9667): 299-40.
[10] Kotseva K, Wood D, De Backer G, et al. EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practise: cross-sectional survey in 12 European countries. Eur J Cardiovasc Prev Rehabil 2010; 17(5): 530-40.
[11] Alsheikh-Ali AA, Omar MI, Raal FJ, et al. Cardiovascular risk factor burden in Africa and the Middle East: the Africa Middle East Cardiovascular Epidemiological (ACE) study. PLoS One 2014; 9(8): e102580.
[12] Alsheikh-Ali AA, Almahmeed W, Porath A, et al. Prevalence and treatment of cardiovascular risk factors in outpatients with atherothrombosis in the Middle East. Heart Asia 2011; 3(1): 77-81.
[13] El-Menyar A, Zubaid M, Shehab A, et al. Prevalence and Impact of cardiovascular risk factors among patients presenting with acute coronary syndrome in the middle East. Clin Cardiol 2011; 34(1): 51-8.
[14] Almahmeed W, Arnaout MS, Chettaoui R, et al. Coronary artery disease in Africa and the Middle East. Ther Clin Risk Manag 2012; 8: 65-72.
[15] Alhyas L, McKay A, Balasanthiran A, Majeed A. Prevalences of overweight, obesity, hyperglycaemia, hypertension and dyslipidaemia in the Gulf: systematic review. JRSM Short Rep 2011; 2(7): 55.
[16] Alhabib KF, Hersi A, Alsheikh-Ali AA, et al. Prevalence, predictors, and outcomes of conservative medical management in non-ST-segment elevation acute coronary syndromes in Gulf RACE-2. Angiology 2012; 63(2): 109-18.
[17] AlJefree N, Ahmed F. Prevalence of cardiovascular disease and associated risk factors among adult population in the Gulf region: A systematic review. Adv Public Health 2015; 2015; Article ID 235101, 23 pages. doi: 10.1155/2015/235101.
[18] Gehani AA, Al-Hinai AT, Zubaid M, et al. Association of risk factors with acute myocardial infarction in Middle Eastern countries: the INTERHEART Middle East study. Eur J Prev Cardiol 2014; 21(4): 400-10.
[19] Al-Suwaidi J, Zubaid M, El-Menyar AA, et al. Prevalence of the metabolic syndrome in patients with acute coronary syndrome in six middle eastern countries. J Clin Hypertens (Greenwich) 2010; 12(11): 890-9.
[20] Al-Rasadi K, Al-Zakwani I, Zubaid M, et al. Prevalence, predictors, and impact of low high-density lipoprotein cholesterol on in-
hospital outcomes among acute coronary syndrome patients in the Middle East. Open Cardiovasc Med J 2011; 5: 203-9.

[21] Arafah M, Al-Hinai AT, Mahmeed WA, et al. Centralized Pan-Middle East survey on the undertreatment of hypercholesterolemia: results from the CEPHEUS Study in Arabian Gulf Countries. Angiology 2014; 65(10): 919-26.

[22] Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary. J Clin Lipidol 2014; 8(5): 473-88.

[23] Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-5.

[24] James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311(5): 507-20.

[25] Alsheikh-Ali AA, Al-Mallah MH, Al-Mahmeed W, et al. Heart failure in patients hospitalized with acute coronary syndromes: observations from the Gulf Registry of Acute Coronary Events (Gulf RACE). Eur J Heart Fail 2009; 11(12): 1135-42.

[26] El-Menyar A, Zubaid A, Rashed W, et al. Comparison of men and women with acute coronary syndrome in six Middle Eastern countries. Am J Cardiol 2009; 104(8): 1018-22.

[27] Shehab A, Al-Dabbagh B, AlHabib KF, et al. Gender disparities in the presentation, management and outcomes of acute coronary syndrome patients: data from the 2nd Gulf Registry of Acute Coronary Events (Gulf RACE-2). PLoS One 2013; 8(2): e55508.

[28] Athyros VG, Ganotakis E, Kolovou GD, et al. Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospective-randomized study in middle aged men and women. Curr Vasc Pharmacol 2011; 9(6): 647-57.

[29] Alagona P Jr, Ahmad TA. Cardiovascular disease risk assessment and prevention: current guidelines and limitations. Med Clin North Am 2015; 99(4): 711-31.